CN113995744B - Composition and antibacterial application thereof - Google Patents
Composition and antibacterial application thereof Download PDFInfo
- Publication number
- CN113995744B CN113995744B CN202111195294.4A CN202111195294A CN113995744B CN 113995744 B CN113995744 B CN 113995744B CN 202111195294 A CN202111195294 A CN 202111195294A CN 113995744 B CN113995744 B CN 113995744B
- Authority
- CN
- China
- Prior art keywords
- acid
- composition
- glycine
- percent
- escherichia coli
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 127
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 26
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims abstract description 105
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 96
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 74
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims abstract description 67
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 66
- 239000001630 malic acid Substances 0.000 claims abstract description 66
- 235000011090 malic acid Nutrition 0.000 claims abstract description 66
- 241000588724 Escherichia coli Species 0.000 claims abstract description 47
- 239000004471 Glycine Substances 0.000 claims abstract description 47
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 39
- 239000001530 fumaric acid Substances 0.000 claims abstract description 37
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 37
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 135
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 64
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 34
- 229960004295 valine Drugs 0.000 claims description 32
- 239000003899 bactericide agent Substances 0.000 claims description 7
- 239000003599 detergent Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000001384 succinic acid Substances 0.000 claims description 6
- 229940124350 antibacterial drug Drugs 0.000 claims description 4
- 235000013373 food additive Nutrition 0.000 claims description 4
- 239000002778 food additive Substances 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 abstract description 55
- 241000894006 Bacteria Species 0.000 abstract description 28
- 235000005985 organic acids Nutrition 0.000 abstract description 17
- 230000001580 bacterial effect Effects 0.000 abstract description 8
- 230000005764 inhibitory process Effects 0.000 abstract description 7
- 244000005700 microbiome Species 0.000 abstract description 6
- 238000009792 diffusion process Methods 0.000 abstract 1
- 230000003385 bacteriostatic effect Effects 0.000 description 25
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 22
- 238000012360 testing method Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- 241000283966 Pholidota <mammal> Species 0.000 description 14
- 239000000654 additive Substances 0.000 description 14
- 230000000996 additive effect Effects 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 239000002207 metabolite Substances 0.000 description 14
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 241000607715 Serratia marcescens Species 0.000 description 9
- 239000006087 Silane Coupling Agent Substances 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 235000013305 food Nutrition 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000000214 mouth Anatomy 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 6
- 239000000416 hydrocolloid Substances 0.000 description 6
- 201000007100 Pharyngitis Diseases 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 229910001887 tin oxide Inorganic materials 0.000 description 5
- 241000192125 Firmicutes Species 0.000 description 4
- 239000006137 Luria-Bertani broth Substances 0.000 description 4
- 241000283956 Manis Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- JHGFRCLDPHKRBS-UHFFFAOYSA-N [Sn+2]=O.[O-2].[Zr+4].[O-2].[O-2] Chemical compound [Sn+2]=O.[O-2].[Zr+4].[O-2].[O-2] JHGFRCLDPHKRBS-UHFFFAOYSA-N 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010068319 Oropharyngeal pain Diseases 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- -1 and among them Substances 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000012459 cleaning agent Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000004332 deodorization Methods 0.000 description 2
- 230000000249 desinfective effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000009438 liyan Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 229940126532 prescription medicine Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- STGNLGBPLOVYMA-MAZDBSFSSA-N (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O STGNLGBPLOVYMA-MAZDBSFSSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000081426 Ranunculus ficaria Species 0.000 description 1
- 235000002226 Ranunculus ficaria Nutrition 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- OVYQSRKFHNKIBM-UHFFFAOYSA-N butanedioic acid Chemical compound OC(=O)CCC(O)=O.OC(=O)CCC(O)=O OVYQSRKFHNKIBM-UHFFFAOYSA-N 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012084 conversion product Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- ZPEZUAAEBBHXBT-RZVRUWJTSA-N l-valine l-valine Chemical compound CC(C)[C@H](N)C(O)=O.CC(C)[C@H](N)C(O)=O ZPEZUAAEBBHXBT-RZVRUWJTSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000028744 lysogeny Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940114496 olive leaf extract Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940064064 purslane extract Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000010267 two-fold dilution method Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/02—Saturated carboxylic acids or thio analogues thereof; Derivatives thereof
- A01N37/04—Saturated carboxylic acids or thio analogues thereof; Derivatives thereof polybasic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/06—Unsaturated carboxylic acids or thio analogues thereof; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/36—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
- A01N37/46—N-acyl derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/42—Preservation of non-alcoholic beverages
- A23L2/44—Preservation of non-alcoholic beverages by adding preservatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3481—Organic compounds containing oxygen
- A23L3/3508—Organic compounds containing oxygen containing carboxyl groups
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3526—Organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
- C11D7/22—Organic compounds
- C11D7/26—Organic compounds containing oxygen
- C11D7/265—Carboxylic acids or salts thereof
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
- C11D7/22—Organic compounds
- C11D7/32—Organic compounds containing nitrogen
- C11D7/3245—Aminoacids
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
- C11D7/22—Organic compounds
- C11D7/32—Organic compounds containing nitrogen
- C11D7/3263—Amides or imides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The inhibition of organic acids inhibits the next generation of bacteria by entering the bacterial cells in a free diffusion manner. The composition of the present invention can control the number of bacteria to a degree harmless to the human body. The invention relates to a composition and its antibacterial application, used for human body and environment application, can reduce the reproduction trend of its existing microorganism, the composition comprises: 1.2% malic acid, 0.3% hippuric acid, 0.1% fumaric acid, 0.1% glycine and water. Wherein the minimum inhibitory concentration of the composition for inhibiting escherichia coli and staphylococcus aureus is 2.5 times lower than that of the composition for inhibiting escherichia coli and staphylococcus aureus by using 1.2% of malic acid, 0.3% of hippuric acid, 0.1% of fumaric acid or 0.1% of glycine alone.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a composition and antibacterial application thereof.
Background
The pangolin scales are used in the Xianfang Huoming drink in the 'woman good prescription' written by Song Dynasty Chen Ming Shuang, and the whole formula has the effects of clearing away heat and toxic materials, eliminating swelling and dissipating hard mass, promoting blood circulation to arrest pain and the like, and has the symptoms of local inflammation and pain. Pangolin scales recorded in Ben Cao gang mu of Ming Dynasty Li Shizhen records that it can eliminate phlegm, malaria, chills and fever, wind-arthralgia, rigidity and pain, dredge meridians, relieve pain and swelling, expel pus and blood, dredge orifices and kill parasites. In the recipe of the recipe, it is mentioned that "diarrhea with grief", pangolin scales and clam powder are stir-baked and ground into powder. As can be seen from the above ancient medical records, pangolin scales are used to treat diseases that modern medicine believes to be caused by bacterial infections. Guo Yi et al reported in the reports of Hunan institute of traditional Chinese medicine (academy of academic), reported that the water decoction of squama Manis has antibacterial effect on 11 kinds of bacteria such as Escherichia coli, wherein the main component of the water decoction is squama Manis.
However, as pangolins are in an extremely endangered state in modern society, 8 pangolins are listed in red record of endangered species in the world natural protection alliance (IUCN) 2014, and are listed in CITES appendix I level of protected animals in the Washington convention in 2016, so that the global trade is prohibited. China is the contracting country of International trade Convention (CITES) on endangered wild animal and plant species. Meanwhile, in 2020, pangolin scales are excluded from Chinese pharmacopoeia and used as medicine. Therefore, the ingredients or ingredient compositions which have the effect of inhibiting the flora in the squama of the pangolin are researched, and the artificial synthesis is carried out to be used as a substitute, so that the endangered animal pangolin can be protected while the relevant treatment scheme for replacing the ingredients of the pangolin is not influenced.
In the prior art, an organic acid is used in various fields as an organic acid additive, and among them, citric acid is used as the organic acid which is used most frequently for preservation and flavor addition. Chinese patent with publication number CN108670897B relates to a high-efficiency bacteriostatic wet tissue composition and a preparation method thereof. The raw materials for preparing the efficient bacteriostatic wet tissue composition comprise, by weight, 1-6 parts of ethanol, 0.5-3 parts of butanediol, 0.2-0.6 part of solubilizer, 0.01-0.02 part of menthol, 0.1-0.12 part of essence, 0.5-1.0 part of tea extract, 0.5-1.0 part of olive leaf extract, nano-silver, 0.5-1.0 part of purslane extract, 0.1-0.2 part of citric acid, 0.05-0.15 part of sodium citrate and 0.01-0.05 part of phenoxyethanol. The composition comprises organic acid citric acid as antibacterial component, wherein phenoxyethanol is used for assisting in dissolving citric acid. However, the existing organic acids are various, and the bacteriostatic effect of citric acid cannot reach the highest bacteriostatic efficiency.
Chinese patent with publication number CN108904374A relates to an oral cavity cleanser, which comprises the following components in parts by weight: 3-8 parts of tea extract, 1-3 parts of persimmon astringent, 1-2 parts of fructose, 2-4 parts of citric acid and 1-3 parts of spice.
Generally speaking, the pH of the mouth wash or other oral cleaning agent is in the range of 6.5-7.5, which is biased toward neutral, so that the use of the mouth wash does not destroy the proteins in the oral cavity and provides excellent bactericidal action in a neutral environment. The glycine buffer consisting of glycine is capable of maintaining the liquid in the range of 2.2-10.6. Pseudomonas aeruginosa and Serratia marcescens are pathogens of opportunistic infections causing immune impairment, and are mostly present at wounds. The oral cavity cleanser prevents pseudomonas aeruginosa and serratia marcescens from entering respiratory tract to cause harm to patients by the function of inhibiting the reproduction of the pseudomonas aeruginosa and the serratia marcescens in the oral cavity.
In the prior art, various weakly acidic bacteriostatic preservative effects are proved, but the application of organic acids with the most extensive and the highest inhibitory effects on human diseases such as escherichia coli and staphylococcus aureus is not found.
According to the experiment, the metabolite composition for inhibiting bacteria in the squama manitis is explored through the component research of the squama manitis with good antibacterial effect, so that the antibacterial effect of replacing the squama manitis with multi-combination weak acid is realized.
Furthermore, on the one hand, due to the differences in understanding to those skilled in the art; on the other hand, since the applicant has studied a great deal of literature and patents when making the present invention, but the disclosure is not limited thereto and the details and contents thereof are not listed in detail, it is by no means the present invention has these prior art features, but the present invention has all the features of the prior art, and the applicant reserves the right to increase the related prior art in the background.
Disclosure of Invention
In order to overcome the defects in the prior art, the invention provides a composition. Is used for human body or environment in which human body is located, and can reduce the propagation tendency of microorganism existing in the environment. The composition comprises: one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid.
Preferably, the ingredients in the composition comprise: (1) malic acid; (2) hippuric acid; (3) optionally at least one of the following weakly acidic components: 1) Glycine; 2) Succinic acid and/or L-valine.
Preferably, the ingredients in the composition comprise: (1) malic acid; (2) hippuric acid; (3) optionally at least one group of weakly acidic components of: 1) Fumaric acid and/or glycine; 2) Succinic acid and/or L-valine.
According to a preferred embodiment, the first component, consisting of malic acid, hippuric acid, succinic acid, L-valine, is formulated together with the second component, consisting of fumaric acid or succinic acid, to form a composition having an inhibitory effect on the growth of microorganisms.
The technical scheme has the advantages that: compared with the application of single organic acid, the organic acid combination formed by multiple combinations can form better antibacterial effect (proved by antibacterial tests) compared with the single organic acid, and different flavors of the disinfection components which are suitable for food, makeup, oral cavity cleaning and the like and act on human bodies are formed by the combination of multiple organic acids, so that the aims of deodorization and refreshment are fulfilled. The formation and decomposition of organic acid are harmless to human body and environment, and the principle of bacteriostasis and sterilization is that small molecules enter the bacterial body and destroy the alkaline active environment in the bacterial body, thereby inhibiting the bacterial activity. The combination of the organic acids in various combinations forms a covalent structure with each other and forms bacteriostatic effects which are mutually increased, and the organic acids which are combined randomly in a single way or a plurality of ways and need to be added in a large dose are replaced by the composition with a smaller dose, so that the harm to human bodies caused by excessive intake of the food additive is reduced.
According to a preferred embodiment, said composition for acting on the human body or on the environment comprises malic acid, hippuric acid, glycine and citric acid, wherein the composition is capable of enhancing the fruity ingredient for acting on the environment in a buffered acidic organoleptic manner, based on the interaction of malic acid and citric acid.
According to a preferred embodiment, the composition comprises at least malic acid, hippuric acid, glycine and citric acid, wherein the components constituting said composition are applied to the skin surface in the form of a non-newtonian fluid.
According to a preferred embodiment, the composition comprises at least malic acid, hippuric acid, glycine and fumaric acid, wherein the components constituting the composition are applied to the skin surface in the form of a non-newtonian fluid.
The technical scheme has the advantages that: drugs and cosmetics used for repairing, treating or protecting skin surfaces cannot be stably hung on the face due to the fluidity of fluid in the process of applying, but paste drugs are not easy to be uniformly applied due to the viscosity. The invention adopts the component form of non-Newtonian fluid, reduces the fluidity of the non-Newtonian fluid and does not change the viscosity, thereby ensuring the stability of the components attached on the face and the skin.
According to a preferred embodiment, the composition is capable of inhibiting the division of escherichia coli and staphylococcus aureus in a synergistic manner.
A composition capable of forming, in the form of a dispersed phase, the cleaning component of an oral cleaning agent together with an abrasive, the composition being for use in inhibiting the growth of escherichia coli and staphylococcus aureus in the interior of the oral cavity, wherein the composition comprises one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine, and citric acid.
A composition which can inhibit the multiplication of Escherichia coli and Staphylococcus aureus on the surface of human skin or in food, wherein the composition comprises one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid.
Antimicrobial use of a composition for application as an additive in a detergent or bactericide, said composition as an additive being provided with means for releasing H + And a second composition for increasing the kill effect and time. The first composition comprises: malic acid, hippuric acid, fumaric acidOne or more of glycine, succinic acid, L-valine and citric acid, and the second composition comprises hydrocolloid. Wherein the first composition intervenes in the second composition when the composition as an additive is applied, and acts on the interior of the bacterial body of Escherichia coli or Staphylococcus aureus accompanying with the coating of the second composition on Escherichia coli or Staphylococcus aureus carried by a target of detergent or bactericide application.
Antibacterial use of a composition for inhibiting the growth of bacteria in tissue inflammation caused by bacterial infection, said medicament comprising as essential components: one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid.
Detailed Description
The following detailed description is made with reference to the accompanying drawings.
The invention relates to a bacteriostatic composition which can achieve the most effective inhibitory action on microorganisms represented by escherichia coli and staphylococcus aureus.
Organic acids used for bacteriostasis include Fumaric acid (Fumaric acid), succinic acid (Succinic acid), L-Valine (L-Valine), malic acid (Malic acid), citric acid (Citric acid), glycine (Glycine), and Hippuric acid (Hippuric acid). The proportion of the extract is consistent with the content of squama Manis, wherein in the total extract (CV), fumaric acid accounts for 0.1%, succinic acid accounts for 0.4%, L-valine accounts for 1.3%, malic acid accounts for 1.2%, citric acid accounts for 0.2%, glycine accounts for 0.1%, and hippuric acid accounts for 0.3%. Preferably, the above ratio is adjustable and effective.
The microorganisms referred to herein can comprise gram-negative bacteria, gram-positive bacteria, or comprise a pathogenic staphylococcal representative, a conditional pathogenic bacterium, such as escherichia coli, or other pathogenic bacteria, such as mycobacterium tuberculosis.
The organic acids used in the experiments and constituting the components of the composition of the present invention are all artificially synthesized organic acids.
By the special content proportion of the composition, the better antibacterial effect of a single or few compositions with the same volume is achieved.
Example 1
The antibacterial metabolites were used for Minimum Inhibitory Concentrations (MIC) detection of Escherichia coli (E.coli; escherichia coli) and Staphylococcus aureus (S.aureus; staphylococcus aureus), pseudomonas aeruginosa (P.aeruginosa; pseudomonas aeruginosa) and Serratia marcescens (S.marcocens) respectively, based on the Minimum Inhibitory Concentration (MIC) test.
(1) Experimental materials:
1) Culture medium
A lysis Broth (LB; lysogeny Broth) medium containing 10g/L of peptone, 5g/L of yeast extract and 10g/L of sodium chloride was used.
2) Antibacterial drugs:
comprises the whole composition consisting of one or more of fumaric acid, succinic acid, L-valine, malic acid, citric acid, glycine and hippuric acid.
(2) The bacteriostatic test comprises the following steps:
1) Preparation of bacterial suspension
And simultaneously recovering the preserved escherichia coli representing gram-negative bacteria and staphylococcus aureus representing gram-positive bacteria. A single colony having a diameter of about 1mm was picked up by using an inoculating loop on a plate of the test bacterium which had been purified, inoculated in 2mL of LB broth, and cultured in a biochemical incubator at 37 ℃. The enriched logarithmic phase strain solution is adjusted to a concentration of 0.5 McLeod's turbidimetric standard (i.e., an absorbance at 625nm is 0.08-0.10) with LB broth, and contains about 1X 10 8 ~2×10 8 CFU·mL -1 。
2) Preparation of antibacterial drugs
Preparing the combined antibacterial agent with concentration of 4C, 2C, 0.5C, 0.25C, 0.125C, 0.0625C, 0.03125C by two-fold dilution method, numbering 8 sterile test tubes in sequence, and adding 1ml of sterile water into 2-8 test tubes. Prepare 2ml 4C's antibacterial agent in first test tube, get the solution in 1ml first test tube and add a second test tube, after the mixing, get the solution in 1ml second test tube again and add a third test tube, dilute in proper order.
3) MIC assay
200. Mu.L of LB broth was added to column 1 of a 96-well plate as a negative control, and 180. Mu.L of the prepared bacterial suspension was added to columns 2-10 to a final concentration of 1X 10 5 CFU·mL -1 . The 2 nd column is added with 20 μ L of sterile water as a positive control group, and the 3 rd to 10 th columns are respectively added with 20 μ L of drugs with final concentrations of 0.4, 0.2, 0.1, 0.05, 0.025, 0.0125, 0.00625 and 0.003125C. The respectively inoculated drug sensitive plates were placed in an incubator at 37 ℃ for 24 hours, MIC values were detected by observing turbidity of LB broth medium and detecting OD values, and the experiment was repeated 3 times.
The results are shown in Table 1, the minimum inhibitory concentration of each metabolite on Escherichia coli and Staphylococcus aureus, the summary of the independently existing concentrated antibacterial metabolites, and malic acid is the best inhibitory effect on Escherichia coli and Staphylococcus aureus.
TABLE 1
In order to verify the optimal effect of malic acid and the composition thereof, the experiment further performed an antibacterial test using malic acid and other metabolites as compositions, and the results represented by MIC values are shown in table 2.
TABLE 2
Experimental results show that the MIC value of the two-component composition added with malic acid on escherichia coli and staphylococcus aureus is reduced, and the two-component composition has a higher inhibition effect on the escherichia coli and the staphylococcus aureus. Still further, random dispensing of the three compositions was performed and the bacteriostatic tests were performed as shown in table 3.
TABLE 3
The combination of malic acid and fumaric acid has a weak rebound of bacteriostatic effect when combined with L-valine or citric acid, and similarly, malic acid and L-valine have the same result when combined with glycine or hippuric acid, and have a weak inhibitory effect on Escherichia coli and Staphylococcus aureus, and the MIC value rises to 0.4C. The composition formed by malic acid, hippuric acid and citric acid has optimal inhibition effect on escherichia coli, and the MIC value is 0.1C.
The experiment also carried out bacteriostatic tests on four compositions consisting of malic acid and other metabolites distributed in the four compositions, wherein malic acid is selected as the main component, and the results are shown in Table 4.
TABLE 4
The results show that the combination of malic acid, fumaric acid, glycine and hippuric acid and the combination of malic acid, citric acid, glycine and hippuric acid are able to develop bacteriostatic effects with MIC as low as 0.1C.
The experiment also carried out bacteriostatic tests on five compositions consisting of malic acid and other metabolites distributed in the main component, and the results are shown in table 5.
TABLE 5
The results show that malic acid, L-valine, citric acid, glycine, hippuric acid; malic acid, fumaric acid, succinic acid, L-valine, hippuric acid; the three compositions of malic acid, fumaric acid, L-valine, glycine and hippuric acid can have an inhibitory effect on escherichia coli with an MIC value of 0.1C. The composition comprises malic acid, succinic acid, L-valine, glycine and hippuric acid; malic acid, fumaric acid, L-valine, citric acid, hippuric acid; malic acid, fumaric acid, citric acid, glycine, hippuric acid; malic acid, succinic acid, L-valine, citric acid, hippuric acid; any one group of malic acid, succinic acid, citric acid, glycine and hippuric acid can have an inhibitory effect on Escherichia coli and Staphylococcus aureus with an MIC value of 0.1C. Compared with the prior art in which a single organic acid or two organic acids are used as the additive, the bacteriostatic effect of the bacteriostatic additive cannot reach that of the bacteriostatic additive formed by combining more than four organic acids.
In the experiment, the results of bacteriostatic tests on six compositions and seven metabolites formed by distributing other metabolites and malic acid by selecting malic acid as a main component are shown in Table 6.
TABLE 6
The results show that even if six or more metabolites are mixed, the bacteriostatic effect on staphylococcus aureus and escherichia coli can reach an MIC value of 0.1C.
Further, the metabolite combinations comprising malic acid, hippuric acid, fumaric acid and glycine were tested for Escherichia coli, staphylococcus metalens, pseudomonas aeruginosa and Serratia marcescens, and the results are shown in Table 7:
TABLE 7
The results show that the organic acid metabolite composition consisting of malic acid, hippuric acid, fumaric acid and glycine has an MIC value of 0.1C for Escherichia coli and Staphylococcus aureus and an MIC value of 0.2C for Pseudomonas aeruginosa and Serratia marcescens. The organic acid metabolite composition comprising malic acid, hippuric acid, fumaric acid and glycine has growth inhibiting effect on bacteria represented by Escherichia coli, staphylococcus metalens, pseudomonas aeruginosa and Serratia marcescens, especially pathogenic bacteria.
Serratia marcescens, which is the smallest bacterium, belongs to gram-negative bacilli and is a conditional pathogen.
Pseudomonas aeruginosa is a gram-negative bacterium, and is an opportunistic infectious bacterium.
Escherichia coli, staphylococcus metal, pseudomonas aeruginosa and serratia marcescens are widely distributed in nature, can enter a human body through the positions of the mouth, the nose and the like of the human body, and cause the human body to generate pathogenic reactions such as inflammation and the like under certain conditions or environmental conditions. Therefore, the four strains are selected as test objects of the bacteriostasis test in the experiment.
Based on the experimental results, the composition consisting of malic acid, glycine and hippuric acid can form an effect of inhibiting the bacteria of staphylococcus aureus and escherichia coli to achieve an MIC value of 0.1C together with citric acid or fumaric acid.
The composition for the experiment can be prepared from 0.1% of fumaric acid, 0.4% of succinic acid, 1.3% of L-valine, 1.2% of malic acid, 0.2% of citric acid, 0.1% of glycine and 0.3% of hippuric acid according to the above proportions.
Preferably, the composition for reducing the tendency of microorganisms present on the surface of the human body or in the environment in which the human body is located to multiply comprises: 0.125 to 0.482 percent of malic acid, 0.135 to 0.422 percent of L-valine, 0.021 to 0.081 percent of citric acid, 0.01 to 0.04 percent of succinic acid, 0.031 to 0.121 percent of hippuric acid, 0.001 to 0.041 percent of glycine and 0.01 to 0.041 percent of fumaric acid.
Preferably, the ratio of the components in the composition can be: 1 to 30 percent of malic acid, 0.1 to 20 percent of L-valine, 0.1 to 20 percent of citric acid, 0.1 to 20 percent of succinic acid, 0.1 to 20 percent of hippuric acid, 0.1 to 20 percent of glycine and 0.1 to 20 percent of fumaric acid.
Preferably, the ratio of the components in the composition can be: malic acid accounts for 10-40% of the total composition, L-valine accounts for 0.01-10% of the total composition, citric acid accounts for 0.01-10% of the total composition, succinic acid accounts for 0.01-20% of the total composition, hippuric acid accounts for 0.01-20% of the total composition, glycine accounts for 0.01-20% of the total composition, and fumaric acid accounts for 0.01-10% of the total composition.
Preferably, the malic acid can be in the range of about 0.1% to about 20%, about 1% to about 10%, about 3% to about 8%, about 6% to about 12%, about 15% to about 18%, about 17% to about 20%, 20% to 60% by weight, or about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 30%, or about 40% by weight, including all ranges and subranges therebetween, in the total composition.
Preferably, the L-valine can range from about 0.01% to about 1%, about 1% to about 10%, about 3% to about 8%, about 6% to about 12%, about 15% to about 18%, about 17% to about 20% by weight, or about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 30%, or about 40% by weight, including all ranges and subranges therebetween, in the total composition.
Preferably, the citric acid can range from about 0.01% to about 2%, about 1% to about 10%, about 3% to about 8%, about 6% to about 12%, about 15% to about 18%, about 17% to about 20% by weight, or about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 30%, or about 40% by weight, including all ranges and subranges therebetween, in the total composition.
Preferably, the succinic acid can range from about 0.1% to about 20%, about 1% to about 10%, about 3% to about 8%, about 6% to about 12%, about 15% to about 18%, about 17% to about 20% by weight, or about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 30%, or about 40% by weight, including all ranges and subranges therebetween, in the total composition.
Preferably, the hippuric acid can range from about 0.1% to about 20%, about 1% to about 10%, about 3% to about 8%, about 6% to about 12%, about 15% to about 18%, about 17% to about 20%, 20% to 60% by weight, or about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 30%, or about 40% by weight of the total composition, including all ranges and subranges therebetween.
Preferably, the glycine can be in the range of about 0.1% to about 2%, about 1% to about 10%, about 3% to about 8%, about 6% to about 12%, about 15% to about 18%, about 17% to about 20% by weight, or about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 30%, or about 40% by weight, including all ranges and subranges therebetween, in the total composition.
Preferably, the fumaric acid can range from about 0.01% to about 20%, about 1% to about 10%, about 3% to about 8%, about 6% to about 12%, about 15% to about 18%, about 17% to about 20% by weight, or about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 30%, or about 40% by weight, including all ranges and subranges therebetween, in the total composition.
Preferably, the combined range of malic acid, L-valine, citric acid, succinic acid, hippuric acid, glycine and fumaric acid can include, but is not limited to, the above-mentioned ratio and combined range.
The composition having an inhibitory effect against escherichia coli with an MIC value of 0.1C is represented by a composition of malic acid, hippuric acid and citric acid, while the composition having an inhibitory effect against escherichia coli and staphylococcus aureus with an MIC value of 0.1C is represented by malic acid, fumaric acid, glycine, hippuric acid; malic acid, citric acid, glycine, hippuric acid. Since all the components forming the composition are weakly acidic components and can be absorbed by the human body as food additives, the above-mentioned multi-component compositions can be applied to various fields as components harmless to the human body. In the prior art, the methods and cognition using organic acids are: any organic acid has the bacteriostatic action, and the organic acid can be added into food or other disinfecting liquid contacting with human body in large dose within the legal allowable range for bacteriostasis. However, when used in large quantities as an additive, organic acids generate conversion products in the body, a small amount of the organic acids depends on metabolism, but a large amount of the organic acids cannot ensure that all the products can be metabolized out of the body in time, so that the large amount of the organic acids can cause harm to the body of the human body within a certain period of time. According to the invention, the optimal bacteriostatic composition is obtained by carrying out bacteriostatic proportioning on the organic acid which can effectively inhibit bacteria, and the addition amount of the edible organic acid can be reduced by increasing the variety of the edible organic acid, so that the food or other food is helped to influence the health of a human body while the preservative effect is ensured.
Example 2
This embodiment is a further improvement of embodiment 1, and repeated contents are not described again.
Take the Liyan tablet for chronic pharyngitis treatment at present as an example. Aiming at chronic pharyngitis caused by bacterial infection, the sore throat relieving tablet can have a good effect on the disease. The ingredients of the sore throat relieving tablet comprise pangolin (prepared), ground beeltle, stiff silkworm, oyster (calcined) and figwort, and the pangolin (prepared) in the ingredients is a forbidden medicine because the pangolin (prepared) is taken from endangered organisms, so that the sore throat relieving tablet can not be used as a prescription medicine or a non-prescription medicine for treating patients. According to the invention, by researching the inhibition effect on flora in squama Manis, especially on Escherichia coli and Staphylococcus aureus, one or more groups of compositions with effective inhibition effect on Escherichia coli and Staphylococcus aureus are found. The main components of the medicine comprise: one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid. When the pangolin scales of the liyan tablet are replaced, on one hand, the replacement component can adopt biological tissue extract with similar components, and on the other hand, the replacement component can also be a metabolite substitute component which is synthesized by people and effectively inhibits bacteria. Preferably, when an artificially synthesized compound is used as the substitute component, it can be a composition designed in this experiment to have one of the most excellent inhibitory effects on gram-negative bacteria represented by escherichia coli and gram-positive bacteria represented by staphylococcus aureus: malic acid, fumaric acid, succinic acid, L-valine, citric acid and glycine. The organic acid can bring fruity taste to the tablets, which is popular with children, thereby increasing the enthusiasm of infants to take medicine.
Example 3
This embodiment is a further improvement of embodiment 1 or embodiment 2, and repeated contents are not described again.
The composition can be used as additive composition in various foods, and is effective in inhibiting Escherichia coli and Staphylococcus aureus in foods. For example, the additive is added into some natural fruit juice, namely the natural flavor is increased through the proportion of malic acid and citric acid, and the preservative effect is realized by inhibiting the growth of escherichia coli and staphylococcus aureus through being matched with the fruit juice in vacuum or sealed package. The main components of the additive comprise: one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid. The presence of malic acid and citric acid, separately or in combination, results in an additive having a fruity flavor.
Example 4
This embodiment is a further improvement on embodiment 1, embodiment 2, or embodiment 3, and repeated details are not repeated.
The composition can also be used for killing bacteria at home or under ordinary living conditions. For example, in the domestic life, bacteriostatic bacteria maintenance of the environment or bacteriostatic washing of clothes, especially staphylococcus aureus, which is harmful to the human body, is required. The disinfection of alcohol or 84 disinfectant is also harmful to human body and is not suitable for families with pregnant women or children. The invention can form the liquid agent for killing bacteria, which is suitable for families with children or pregnant women, based on the composition of the weakly acidic components and matched with other components which do not harm the bacteria.
The composition of organic acids can be applied as an additive in detergents or bactericides. The composition as additive is used for clothes or environmental bacteriostasis and deodorization. The composition is provided with a first composition comprising a PH modifier and a second composition for increasing the disinfecting effect and time. The first composition comprises any one of two combinations: malic acid, glycine, hippuric acid and citric acid; malic acid, glycine, hippuric acid and fumaric acid. The second composition comprises a hydrocolloid.
Hydrocolloids, which contain polysaccharides and proteins, form a gel network. When the gel network wraps escherichia coli or staphylococcus aureus carried by a target applied by detergent or bactericide, the first composition existing in the hydrocolloid enters the thallus from the thallus based on the pressure of the gel network on the thallus, the first composition and the second composition act together to form organic acid with synergistic effect, and H is released inside the thallus + Thus, the alkaline environment inside the cells is destroyed, and the activity of the cells is suppressed. The first composition intervenes in the hydrocolloid and acts inside the thallus of the escherichia coli or the staphylococcus aureus along with the wrapping of the hydrocolloid on the escherichia coli or the staphylococcus aureus carried by a target applied by the detergent or the bactericide.
The molecular diameter of the organic acid used to act on the intracellular environment of the bacterium can be smaller than the diameter of the cell membrane channel of escherichia coli and staphylococcus aureus so that the organic acid molecule can enter the interior of the bacterium from the cell membrane channel and destroy the alkaline environment of the interior of the bacterium to inhibit the activity of the bacterium cell.
The joint inhibition effect of the escherichia coli and the staphylococcus aureus is realized through the synergistic effect of a first composition consisting of malic acid, glycine and hippuric acid and a second composition consisting of citric acid or fumaric acid.
Example 5
This embodiment is a further improvement on embodiment 1, embodiment 2, embodiment 3, or embodiment 4, and repeated details are not repeated.
The present invention contemplates a composition for spreading onto a target surface and killing and inhibiting escherichia coli and staphylococcus aureus bacteria by spraying, atomizing or otherwise forming a small particle gas or liquid.
The composition consists of combined liquid or gas particles. The liquid or gas particles comprise a particle core composed of organic acid with high bacteriostasis and an outer coating film which is covered on the particle core and is composed of zirconium oxide-tin oxide complex with nanometer inorganic micropore shape neutralized by silane coupling agent and used for protecting and increasing the adhesive capacity.
By dispersing the zirconium oxide-tin oxide complex in the form of nano-scale inorganic micropores neutralized by the silane coupling agent wrapping the organic acid in the manner of aerosol, aerosol or small-particle liquid in clothes and living environment, when the zirconium oxide-tin oxide complex in the form of nano-scale inorganic micropores neutralized by the silane coupling agent wrapping the organic acid touches escherichia coli and staphylococcus aureus on the target surface, the outer membrane releases the organic acid under pressure and allows the organic acid to enter the bacteria body through the cell membrane on the bacteria surface, thereby inhibiting the bacterial activity. The nano-scale inorganic micropores formed by the zirconia-tin oxide composite can allow organic acid molecules to enter and exit and limit the obstruction of the decomposition and attachment of the particles by large-volume particles. The zirconia-tin oxide composite can effectively maintain the hardness and the toughness of the outer coating film for preventing the collapse of nano-micropores when the outer coating film of particles existing in the forms of aerosol, liquid or gas is formed.
Preferably, the ratio of the silane coupling agent to the nano-scale inorganic microporous form of the zirconia-tin oxide composite is from 1. The ratio of the nano-inorganic microporous zirconium oxide-tin oxide composite to the organic acid is 1 to 1.
Microparticles composed of organism-inorganic bodies coupled with a silane coupling agent can move toward a target surface in a state of a diameter of at least less than 10 μm. The above microparticles have excellent dispersion stability in an aqueous phase for dilution or homogeneous liquid phase, a high adhesion rate of the organic acid carried on the target surface, and a high volatility of the organic acid core reduced by the coating of the outer membrane. The organic-inorganic hybrid membrane is characterized in that an intermediate phase which is low in cost and can stably couple an internal organic layer and an external inorganic layer is utilized, the inorganic layer which is coupled with the organic layer and does not generate other chemical reactions is added under the condition of not damaging the dissociation of hydrogen ions of the organic layer, and the problems of poor adhesion, no effect and volatility of the organic layer on a target surface are solved through the property of the inorganic layer. Preferably, the silane coupling agent coupling can be an aqueous silane coupling agent coupling.
The preparation method of the composition comprises the following steps:
(1) Weighing: weighing the silane coupling agent coupling and zirconia-tin oxide composite (which can be present in the form of a sol) in proportion by weight, and weighing the organic acid composition in terms of volume;
(2) Mixing: and (3) putting the zirconium oxide and tin oxide complex into organic acid in batches, uniformly mixing, slowly pouring a silane coupling agent along with stirring action for coupling, and stirring until three phases are uniform to obtain the concentrated composition.
The concentrated composition can be diluted with water before use, and sprayed to the target surface to be disinfected such as environment or clothes by using equipment such as an aerosol sprayer and a spray can.
The organic acid in the particle core can be combined with the organic acid which is related to the embodiment and can achieve the MIC of 0.1C on the antibacterial effect of escherichia coli and staphylococcus aureus. The organic acid composition wrapped by the outer involucra has good stability in water and has high-efficiency inhibition effect on escherichia coli and staphylococcus aureus.
Example 6
This embodiment is a further improvement on embodiment 1, embodiment 2, embodiment 3, embodiment 4, or embodiment 5, and repeated contents are not described again.
Aiming at the organic acid composition which can be permanently attached to the surface and acts on bacteria, the invention can design an antibacterial ointment or spray which contains one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid and can act on the skin surface or mucous membrane of the face, arms, important organs and the like. The organic acid composition has obvious bacteriostatic action on the propagation of various pathogenic skin bacteria such as gram-negative bacteria, gram-positive bacteria and the like represented by escherichia coli and staphylococcus aureus.
Preferably, the antibacterial ointment comprises traditional Chinese medicine ointment, traditional Chinese medicine powder, mussel mucin and an organic acid composition containing one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid.
Preferably, the bacteriostatic spray comprises pentanediol, 1,3 propanediol and an organic acid composition containing one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid.
It should be noted that the above-mentioned embodiments are exemplary, and that those skilled in the art, having benefit of the present disclosure, may devise various arrangements that are within the scope of the present disclosure and that fall within the scope of the invention. It should be understood by those skilled in the art that the present specification and figures are illustrative only and are not limiting upon the claims. The scope of the invention is defined by the claims and their equivalents. The present description contains a plurality of inventive concepts such as "preferably", "according to a preferred embodiment" or "optionally" each indicating that the respective paragraph discloses a separate concept, the applicant reserves the right to apply for divisional applications according to each inventive concept. Throughout this document, the features referred to as "preferably" are only an optional feature and should not be understood as necessarily requiring that such applicant reserves the right to disclaim or delete the associated preferred feature at any time.
Claims (9)
1. A composition for spraying onto a human body surface or onto the environment in which the human body is located, comprising: 1.2 percent of malic acid, 0.3 percent of hippuric acid, 0.2 percent of citric acid, 0.1 percent of glycine and the balance of water, and the composition cleans a human body or the environment where the human body is positioned in a mode of inhibiting the propagation of escherichia coli and staphylococcus aureus.
2. The composition of claim 1, wherein the composition further comprises: the mass percent of the L-valine is 1.3 percent.
3. The composition according to claim 1 or 2, characterized in that it further comprises: the mass percent is 0.4 percent of succinic acid.
4. Use of the composition according to claim 1 for the preparation of a detergent, an antibacterial drug, a bactericide or a food additive.
5. A composition, comprising: 0.1 percent of fumaric acid, 1.2 percent of malic acid, 0.3 percent of hippuric acid, 0.1 percent of glycine and the balance of water.
6. The composition of claim 5, wherein the composition further comprises: 1.3% L-valine.
7. The composition according to claim 5 or 6, characterized in that it further comprises: 0.2% citric acid.
8. Use of a composition according to claim 5 in the preparation of an oral cleanser.
9. Use of the composition according to claim 5 for the preparation of a detergent, an antibacterial drug, a bactericide or a food additive.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111195294.4A CN113995744B (en) | 2021-10-13 | 2021-10-13 | Composition and antibacterial application thereof |
LU102887A LU102887B1 (en) | 2021-10-13 | 2021-12-16 | Composition and antibacterial usage thereof |
PCT/CN2022/124947 WO2023061416A1 (en) | 2021-10-13 | 2022-10-12 | Composition and antibacterial use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111195294.4A CN113995744B (en) | 2021-10-13 | 2021-10-13 | Composition and antibacterial application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113995744A CN113995744A (en) | 2022-02-01 |
CN113995744B true CN113995744B (en) | 2023-03-17 |
Family
ID=79922851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111195294.4A Active CN113995744B (en) | 2021-10-13 | 2021-10-13 | Composition and antibacterial application thereof |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN113995744B (en) |
LU (1) | LU102887B1 (en) |
WO (1) | WO2023061416A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113995744B (en) * | 2021-10-13 | 2023-03-17 | 温州肯恩大学 | Composition and antibacterial application thereof |
CN115466652A (en) * | 2022-09-21 | 2022-12-13 | 云南水星生物科技有限公司 | Antibacterial color fixative and preparation method and application thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1095801A (en) * | 1999-10-19 | 2001-04-30 | Procter & Gamble Company, The | Antimicrobial compositions comprising a biologically active organic acid |
EP1483975A1 (en) * | 2003-06-05 | 2004-12-08 | PURAC Biochem BV | Antimicrobial composition comprising a mixture of lactic acid or a derivative thereof and an inorganic acid |
KR20130123489A (en) * | 2012-05-03 | 2013-11-13 | 이상현 | Microbicide compositions using vitamin b1 derivatives and effective microorganism |
ES2772931T3 (en) * | 2015-02-05 | 2020-07-08 | Hygienix Bv | Procedure to disinfect a surface, and composition suitable for use on it |
CN107212236A (en) * | 2017-06-26 | 2017-09-29 | 苏州凌科特新材料有限公司 | A kind of composite biological preservative and preparation method thereof |
WO2019078173A1 (en) * | 2017-10-16 | 2019-04-25 | 株式会社日本抗菌総合研究所 | Antimicrobial composition |
WO2019099946A1 (en) * | 2017-11-17 | 2019-05-23 | Renovion, Inc. | Stable ascorbic acid compositions and methods of using the same |
CN108904374A (en) * | 2018-07-24 | 2018-11-30 | 常州市嘉乐钢板网制造有限公司 | Cleaning agent for mouth cavity |
KR101976709B1 (en) * | 2018-08-08 | 2019-05-09 | 주식회사 세니젠 | Antimicrobial composition with malic acid, citric acid and phytic acid |
CN113995744B (en) * | 2021-10-13 | 2023-03-17 | 温州肯恩大学 | Composition and antibacterial application thereof |
-
2021
- 2021-10-13 CN CN202111195294.4A patent/CN113995744B/en active Active
- 2021-12-16 LU LU102887A patent/LU102887B1/en active
-
2022
- 2022-10-12 WO PCT/CN2022/124947 patent/WO2023061416A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
LU102887B1 (en) | 2022-12-01 |
CN113995744A (en) | 2022-02-01 |
WO2023061416A1 (en) | 2023-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3223833B1 (en) | Prevention and treatment of microbial infections | |
CN104274490B (en) | Bactericidal composition including source of silver ions and menthol and application thereof | |
CN101278896B (en) | Chitosan nano silver gel agent and uses thereof | |
CN113995744B (en) | Composition and antibacterial application thereof | |
CN109316536A (en) | A kind of skin mucosa disinfecting agent and preparation method thereof | |
CN110075036A (en) | Anti- oral helicobacter pylori medicated toothpaste | |
CN106309237A (en) | Hyaluronic acid private part care gel and preparation method thereof | |
KR20180051501A (en) | Antimicrobial compositions and formulations that release hydrogen peroxide | |
CN116036137A (en) | Antibacterial and antiviral drug, antibacterial and antiviral component, and method for producing antibacterial and antiviral drug | |
CN102028705A (en) | Gynecologic article containing biological antifungal components | |
CN109077945A (en) | Combined bacteriostat with lysozyme for cosmetics | |
CN111568919A (en) | A preparation containing chitosan oligosaccharide for resisting helicobacter pylori | |
CN101543658A (en) | Cervical cap for preventing and treating cervical erosion and preparation method thereof | |
BR112021007347A2 (en) | BIOFLAVONOID COMPOSITIONS AND THEIR USE FOR WATER PURIFICATION AND FOOD PRESERVATION | |
WO2008104076A1 (en) | Electrocolloidal silver and echinacea root antimicrobial formulation | |
CN1367018A (en) | Compound preparation of staphylococcolysis enzyme and its preparation method and application | |
CN111500490A (en) | Microbial type bacteriostatic and odor-removing preparation as well as preparation method and application thereof | |
KR102251911B1 (en) | Silver ion bacteriostatic hand sanitizer and preparation method and application thereof | |
CN104000767B (en) | A kind of Feminine care solution and preparation method thereof | |
CN102698302B (en) | Dedicated vegetal air disinfectant for medical institution | |
CN103520702A (en) | Cow udder cleaning agent used for preventing bovine mastitis | |
CN103719167A (en) | Degerming agent specially used for aeromonas hydrophila water body | |
CN107802799A (en) | A kind of Medical antiseptic solution | |
CN111246871A (en) | Composition with inhibitory effect on virus and bacteria | |
CN102895282B (en) | Isatis root extracting solution and nano-silver bacteriostatic composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230801 Address after: Workstation 11, Wenzhou Ken University Creative Space, No. 88 Daxue Road, Li'ao Street, Ouhai District, Wenzhou City, Zhejiang Province, 325000 Patentee after: Wenzhou Lien Biotechnology Co.,Ltd. Address before: 325060 No. 88, University Road, Ouhai District, Wenzhou City, Zhejiang Province Patentee before: Wenzhou-Kean University |
|
TR01 | Transfer of patent right |